INS and type 2 diabetes mellitus: In conclusion, the results from this trial demonstrated that the basal insulin, IDeg, as add-on to 1–2 OADs dosed once daily at any time of the day, was superior to Sita in terms of improving glycaemic control as measured by reduction in HbA1c in subjects with type 2 diabetes.